18 Jul 2017
N+1 Singer - Abzena - Licence agreement for Abzena’s PSMA antibodies
The licensing agreement with Telix Pharmaceuticals to develop products for the imaging and treatment of prostate cancer is great news and illustrates the commercial potential of Abzena’s Composite Human Antibody™ technology. Under the terms of the agreement, Abzena could receive in excess of $65m in licence fees and milestone payments as well as potential royalties on product sales. A separate services agreement has also been established, validating the group’s combined services and licence fee ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Abzena - Licence agreement for Abzena’s PSMA antibodies
Abzena (ABZA:LON) | 0 0 (-0.9%) | Mkt Cap: 54.0m
- Published:
18 Jul 2017 -
Author:
Dr Jens Lindqvist -
Pages:
3
The licensing agreement with Telix Pharmaceuticals to develop products for the imaging and treatment of prostate cancer is great news and illustrates the commercial potential of Abzena’s Composite Human Antibody™ technology. Under the terms of the agreement, Abzena could receive in excess of $65m in licence fees and milestone payments as well as potential royalties on product sales. A separate services agreement has also been established, validating the group’s combined services and licence fee ....